Jenna Kahn M.D. is an assistant professor in the Department of Radiation Medicine. Dr. Kahn’s clinical work focuses primarily on gynecologic and genitourinary cancer with a specialty in high dose rate (HDR) brachytherapy. In addition to seeing patients, she continues to be passionate in clinical and education research. In medical school, she was awarded the Clinical Research Training Program Fellowship at the National Institutes of Health. After medical school, she completed her residency at Virginia Commonwealth University and received her Bachelors of Science and Medical Degree from Brown University. She is an active member in the American Society of Radiation Oncology, American Society of Clinical Oncology, Radiation Oncology Institute, American College of Radiology, Society of Women in Radiation Oncology, and OHSU Knight Cancer Institute Translational Oncology Program. Dr. Kahn has particular interests in medical student and residency education, social media advocacy, brachytherapy, and patient education especially in sexual health.
- Determining and understanding the utilization of brachytherapy for gynecologic, prostate, and breast cancers
- Sexual health in female cancer patients
- Improving education and hands on training modules for radiation oncology and ob/gyn residents in brachytherapy
- Promoting and improving education for residents in radiation oncology including transitioning from residency to attending and practical hands on modules and tools
- Social media in radiation oncology, understanding, use, and advocacy both for physicians and patients
- Communications within radiation oncology
- Gender equity and advocacy for females in radiation oncology
- Loise Wairiri, MBBS
- Adam Eakin (Medical student, OHSU)
- Julia Drizin (Ph.D. student, Oregon State University)
- Daanya Siddiqui (High school student)
- Lucie Le Rutt (High school student)
- Jessica Gorman Ph.D., MPH, Oregon State University
- Lisa Egan, P.A.
- Melissa Moffitt, M.D.
- Emma Fields, M.D.
Networking and Applying to Radiation Oncology During A Pandemic: Cross-Sectional Survey of Medical Student Concerns. Pollom EL, Sandhu N, Deig CR, Obeid JP, Miller JA, Kahn JM. Advances in Radiation Oncology (2021), doi: https://doi.org/10.1016/j.adro.2021.100643.
#ThisIsBrachytherapy: Increasing awareness of brachytherapy. Kahn JM, Campbell SR, Albert AA, Knoll MA, Shah C. Brachytherapy. 2021 Jan-Feb;20(1):232-236. doi: 10.1016/j.brachy.2020.07.003.
Increasing Medical Student Engagement Through Virtual Rotations in Radiation Oncology. Kahn JM, Fields EC, Pollom E, Wairiri L, Vapiwala N, Nabavizadeh N, Thomas CR Jr, Jimenez RB, Chandra RA. Adv Radiat Oncol. 2021 Jan-Feb;6(1):100538. doi: 10.1016/j.adro.2020.07.015.
Transitioning Roles from Residency to Attending Physician in Radiation Oncology. Kahn JM, DiazGranados D, Fields, E. J Canc Educ (2021). doi.org/10.1007/S13187-020-01936-6.
Authors' response. Kahn JM, Moghanaki D. Brachytherapy. 2020 Jul-Aug;19(4):555. doi: 10.1016/j.brachy.2020.04.006. PMID: 32674913.
Distancing Without Isolating—Connection in the Era of COVID-19. Cook KA, Kahn JM. JAMA Oncol. Published online July 23, 2020. doi:10.1001/jamaoncol.2020.2725
Rectal spacing, prostate coverage, and periprocedural outcomes after hydrogel spacer injection during low-dose-rate brachytherapy implantation. Kahn J, Dahman B, McLaughlin C, Kapoor P, Kapoor R, Harris E, Sharma M, Schutzer M, Moghanaki D. Brachytherapy. 2020 Mar - Apr;19(2):228-233. doi: 10.1016/j.brachy.2019.11.002.
Top Concerns of Radiation Oncology Trainees in 2019: Job Market, Board Examinations, and Residency Expansion. Kahn J, Goodman CR, Albert A, Agarwal A, Jeans E, Tye K, Campbell SR, Marcrom S, Colbert LE. Int J Radiat Oncol Biol Phys. 2020 Jan 1;106(1):19-25. doi: 10.1016/j.ijrobp.2019.07.006.
Modernization of Board Certification in Radiation Oncology: Opportunities Following COVID-19. Goodman CR, Campbell SR, Jeans EB, Agarwal A, Tye K, Kahn JM. Int J Radiat Oncol Biol Phys. 2020 Oct 1;108(2):458-461. doi: 10.1016/j.ijrobp.2020.06.039.PMID: 32890532
A Survey Study of Female Radiation Oncology Residents' Experiences to Inform Change. Osborn VW, Doke K, Griffith KA, Jones R, Lee A, Maquilan G, Masters AH, Albert AA, Dover LL, Puckett LL, Hentz C, Kahn JM, Colbert LE, Barry PN, Jagsi R. Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):999-1008. doi: 10.1016/j.ijrobp.2019.05.013. Epub 2019 May 17.
Brachytherapy Training Survey of Radiation Oncology Residents. Marcrom SR, Kahn JM, Colbert LE, Freese CM, Doke KN, Yang JC, Yashar CM, Luu M, Kamrava M. Int J Radiat Oncol Biol Phys. 2019 Mar 1;103(3):557-560. doi: 10.1016/j.ijrobp.2018.10.023. Epub 2018 Oct 26.
Interobserver reliability in describing radiographic lung changes after stereotactic body radiation therapy. Kalman NS, Hugo GD, Kahn JM, Zhao SS, Jan N, Mahon RN, Weiss E. Adv Radiat Oncol. 2018 May 25;3(4):655-661. doi: 10.1016/j.adro.2018.05.004. eCollection 2018 Oct-Dec.
The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Durant ST, Zheng L, Wang Y, Chen K, Zhang L, Zhang T, Yang Z, Riches L, Trinidad AG, Fok JHL, Hunt T, Pike KG, Wilson J, Smith A, Colclough N, Reddy VP, Sykes A, Janefeldt A, Johnström P, Varnäs K, Takano A, Ling S, Orme J, Stott J, Roberts C, Barrett I, Jones G, Roudier M, Pierce A, Allen J, Kahn J, Sule A, Karlin J, Cronin A, Chapman M, Valerie K, Illingworth R, Pass M. Sci Adv. 2018 Jun 20;4(6):eaat1719. doi: 10.1126/sciadv.aat1719. eCollection 2018 Jun.
Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice. Karlin J, Allen J, Ahmad SF, Hughes G, Sheridan V, Odedra R, Farrington P, Cadogan EB, Riches LC, Garcia-Trinidad A, Thomason AG, Patel B, Vincent J, Lau A, Pike KG, Hunt TA, Sule A, Valerie NCK, Biddlestone-Thorpe L, Kahn J, Beckta JM, Mukhopadhyay N, Barlaam B, Degorce SL, Kettle J, Colclough N, Wilson J, Smith A, Barrett IP, Zheng L, Zhang T, Wang Y, Chen K, Pass M, Durant ST, Valerie K. Mol Cancer Ther. 2018 Aug;17(8):1637-1647. doi: 10.1158/1535-7163.MCT-17-0975. Epub 2018 May 16.
Primary Treatment Options for High-Risk/Medically Inoperable Early Stage NSCLC Patients. Jones GC, Kehrer JD, Kahn J, Koneru BN, Narayan R, Thomas TO, Camphausen K, Mehta MP, Kaushal A. Clin Lung Cancer. 2015 Nov;16(6):413-30. doi: 10.1016/j.cllc.2015.04.001. Epub 2015 Apr 23. Review.
Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Kahn J, Gillespie A, Tsokos M, Ondos J, Dombi E, Camphausen K, Widemann BC, Kaushal A. Front Oncol. 2014 Nov 17;4:324. doi: 10.3389/fonc.2014.00324. eCollection 2014.
The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. Kahn J, Hayman TJ, Jamal M, Rath BH, Kramp T, Camphausen K, Tofilon PJ. Neuro Oncol. 2014 Jan;16(1):29-37. doi: 10.1093/neuonc/not139. Epub 2013 Dec 4.
Competitive but Not Allosteric mTOR Kinase Inhibition Enhances Tumor Cell Radiosensitivity. Hayman TJ, Kramp T, Kahn J, Jamal M, Camphausen K, Tofilon PJ. Transl Oncol. 2013 Jun 1;6(3):355-62. Print 2013 Jun.
Preclinical models in radiation oncology. Kahn J, Tofilon PJ, Camphausen K. Radiat Oncol. 2012 Dec 27;7:223. doi: 10.1186/1748-717X-7-223. Review.
Long-term outcomes of patients with spinal cord gliomas treated by modern conformal radiation techniques. Kahn J, Loeffler JS, Niemierko A, Chiocca EA, Batchelor T, Chakravarti A. Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):232-8. doi: 10.1016/j.ijrobp.2010.05.009. Epub 2010 Oct 13.
Jenna Kahn, M.D., assistant professor, was named as an #ASTRO20 Social Champion for the virtual 2020 ASTRO Annual Meeting. Social Champions serve as ambassadors on social media during the meeting held on October 25 - October 28, 2020. The Social Champions are active participants throughout the course of the meeting, sharing important science, interesting topics, attending social events and more!